Prodromal Schizophrenia
18
3
5
7
Key Insights
Highlights
Success Rate
70% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 72/100
16.7%
3 terminated out of 18 trials
70.0%
-16.5% vs benchmark
6%
1 trials in Phase 3/4
29%
2 of 7 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 7 completed trials
Clinical Trials (18)
Accelerated TMS in Psychosis
Effects of NAC on Symptoms of CHR Patients
Early Intervention of Prodromal Schizophrenia Using an NMDA Enhancer
Evaluation of Step-Based Care for Individuals at Clinical High Risk for Psychosis
Family-Focused Therapy for Individuals at High Clinical Risk for Psychosis: A Confirmatory Efficacy Trial
Targeting Processing Speed Deficits to Improve Social Functioning and Lower Psychosis Risk
EPI-MINN: Targeting Cognition and Motivation - National
REtinal and VIsual Cortical Response in Early PSYchosis
Feasibility Trial of a Lifestyle Intervention for CHR-P
Neurofeedback Training for High Risk Psychosis
Investigating the Role of Diazepam on Brain Function and Chemistry in Psychosis Risk
"Multimodal Prevention of Psychosis - Investigating Efficacy of N-Acetylcysteine and Psychotherapy in CHR-Patients"
Early Detection and Intervention for Women At-risk of Psychosis
Psychosis: Early Detection, Intervention and Prevention
Effects of Cognitive Remediation on Cognition in Young People at Clinical High Risk of Psychosis
Second-Generation Antipsychotic Treatment Indication Effectiveness And Tolerability In Youth (Satiety) Study
Antidepressant and Antipsychotic to Treat Attenuated Positive and Negative Symptoms
Aripiprazole Treatment of the Prodrome